Results 41 to 50 of about 1,629 (148)

Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance

MedComm, Volume 7, Issue 8, August 2026.
The graphical abstract is a schematic illustration of the bidirectional crosstalk between tumor plasticity and the tumor microenvironment (TME) in driving metastasis and therapy resistance. Tumor‐intrinsic factors such as genetic mutations and epigenetic reprogramming enable dynamic transitions between epithelial, mesenchymal, and cancer stem cell ...
Gunjan Dagar, Manisha Dagar, Ashna Gupta, Anju Surendranath, Suraja Kumar Das, Mohd Umar Rehmani, Mukesh Tanwar, Sameer Mirza, Muzafar A. Macha, Ammira S. Al‐Shabeeb Akil, Shahab Uddin, Mayank Singh, Ajaz A. Bhat   +12 more
wiley   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm with Lung Involvement and Cytopenia: A Case Report and a Literature Review

Clinical, Cosmetic and Investigational Dermatology, 2023
Fang Liu,1 Fei Qi,2 Jingya Zhang,1 Yaqi Tan,1 Xiuying Zhang1 1Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Dermatology, Peking Union Medical College Hospital ...
Liu F, Qi F, Zhang J, Tan Y, Zhang X
doaj  

Genetic analysis of primary lung interdigitating dendritic cell sarcomas

The Journal of Pathology, Volume 269, Issue 4-5, Page 387-398, August 2026.
Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov, Juliana Faria Filipe, Sylvia Eidenhammer, German Ott, Iris Halbwedl, Karl Kashofer, Helmut Popper   +6 more
wiley   +1 more source

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of Investigative Medicine High Impact Case Reports, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed
Prashanth Ashok Kumar MBBS, Mulham Ombada MBBS, Gayatri Pemmasani MBBS, Ajay Tambe MBBS, Katalin Banki MD, Teresa Gentile MD, PhD   +5 more
doaj   +1 more source

Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies

International Journal of Laboratory Hematology, Volume 48, Issue 4, Page 795-806, August 2026.
ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala, Anna Maria Della Corte, Angela Bertolini, Marisa Gorrese, Francesca Picone, Bianca Serio, Danilo De Novellis, Laura Mettivier, Luca Pezzullo, Maria Carmen Martorelli, Denise Morini, Matteo D'Addona, Bianca Cuffa, Carmine Selleri, Valentina Giudice   +14 more
wiley   +1 more source

Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm

Nature Communications, 2019
Translocation of (6;8)(p21;q24), a recurrent abnormality of blastic plasmacytoid dendritic cell neoplasm, involves adjacent MYC and RUNX2 regions. Here, the authors show that the RUNX2 super-enhancer is hijacked to activate MYC in addition to RUNX2 ...
Sho Kubota, Kenji Tokunaga, Tomohiro Umezu, Takako Yokomizo-Nakano, Yuqi Sun, Motohiko Oshima, Kar Tong Tan, Henry Yang, Akinori Kanai, Eisaku Iwanaga, Norio Asou, Takahiro Maeda, Naomi Nakagata, Atsushi Iwama, Kazuma Ohyashiki, Motomi Osato, Goro Sashida   +16 more
doaj   +1 more source

Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science

The Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.
Abstract Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for ...
Ya‐Feng Wen, Xiaoning Wang, Sarandeep Boyanapalli, Lee Anderson, Thao Dang, Guan Xing, Marianna Calvet, Tiffany Hart, Sreeneeranj Kasichayanula, Xiaochen Zhao   +9 more
wiley   +1 more source

An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study

Cancer Science, Volume 117, Issue 7, Page 1921-1934, July 2026.
An immune dysfunction score (IDS) provides independent prognostic information in MDS and CMML, complements current risk models, mirrors disease changes, and reflects underlying immune impairment. IDS may also highlight therapeutic sensitivities, supporting its use as a practical biomarker for risk stratification and clinical follow‐up.
Yu‐Hung Wang, Carmelo Gurnari, Valeria Visconte, Arda Durmaz, Luca Guarnera, Wan‐Hsuan Lee, Chi‐Yuan Yao, Andres Jerez, Kristian Gurashi, Kiran Batta, Hsin‐An Hou, Wen‐Chien Chou, Mrinal S. Patnaik, Jaroslaw Maciejewski, Daniel H. Wiseman, Chien‐Chin Lin, Hwei‐Fang Tien   +16 more
wiley   +1 more source

Acute Myeloid Leukemia With Florid Plasmacytoid Dendritic Cell Expansion and Aberrant Expression of CD19

International Journal of Laboratory Hematology, EarlyView.
Afshin Shameli, Russell K. Dorer
wiley   +1 more source

Monocyte maturation pattern by flow cytometry expression of CD64, CD300e, and CD14 correlates to presence of myeloid neoplasm and helps identify blast equivalents in the setting of monocytic neoplasm

Cytometry Part B: Clinical Cytometry, Volume 110, Issue 3, Page 149-159, May 2026.
Abstract CD300e is a marker of mature monocytes in flow cytometry; however, there is limited detailed information on staining patterns in conjunction with other monocyte markers. We evaluated the flow cytometric staining patterns of CD64, CD14, and CD300e in 12 negative and 33 positive peripheral blood specimens and 16 negative and 56 positive bone ...
Jenny Zhang, Jacob Kaplan, Elizabeth Courville   +2 more
wiley   +1 more source